OneVentures Welcome Image

OneVentures is a venture capital firm headquartered in Sydney, Australia that provides human and investment capital into high growth companies with a particular focus on transformative technologies.

The firm is particularly focused on opportunities originating in Australia which are poised to expand into the established and emerging global markets.

All of our Partners have founded, built and exited high-growth businesses.

Our goal is to be the leading Australian early stage venture capital company.

Proudly supporting

Heads Over Heels
Investor Portal Log In

Connect With Us

About OneVentures

OneVentures is a venture capital firm that invests in emerging Australian technology companies with true breakout potential, differentiated technology and compelling business models in the healthcare, education, mobile, media, cloud computing and data, security and privacy, machine learning, sensors and robotics, and food security sectors.

OneVentures is managed by a team of Partners with a skill-set and track record ideally suited to collaboration with entrepreneurial management teams to foster growth and create value: a unique blend of highly successful entrepreneurs, technology business founders and corporate executives with a strong scientific pedigree, extensive off-shore experience and networks.

The OneVentures team is committed to deliver investor returns by applying this expertise to select portfolio companies with significant potential then accelerating their performance.


OneVentures Management Pty Ltd is a designate under OneVentures Nominees Pty Ltd's AFSL (Licence No: 462825) issued by the Australian Securities and Investments Commissions, authorising the Manager to provide such financial services as the Manager provides during the course of its duties as manager of the Fund.

The OneVentures Team

All Partners have many years of C-level, board and investment experience. Coupled with this is a track record of identifying investment opportunities in global markets with strong international business backgrounds and networks. The OneVentures Investment team has 7 technology related higher degrees.

Dr Michelle Deaker

Dr Michelle Deaker
Managing Director and CEO

Dr Paul Kelly

Dr Paul Kelly
Partner and Managing Director

Anne-Marie Birkill

Anne-Marie Birkill
General Partner and Executive Director

Dean Hawkins

Dean Hawkins
Managing Partner

Daniel Gammell

Daniel Gammell
Investment Manager

Michelle Wee

Michelle Wee
Marketing and Communications

Helen Liu

Helen Liu
Chief Financial Officer

Jelly Jakob

Jelly Jakob


Innovation Fund (Fund I)

The OneVentures Innovation Fund is a $40M venture capital fund formed as an early stage venture capital Limited Partnership. This Fund was launched in 2010 with the Commonwealth Government committing $20M from its IIF programme and this funding matched by high net-worth wholesale investors.

Innovation and Growth Fund (Fund II)

The OneVentures Innovation and Growth Fund was launched in March 2014 with a target of $100M and has reached first close of $60M as of October 2014. Fund II is an early stage venture capital limited partnership backed entirely by Australian high net-worth wholesale investors.

Focusing on later stage (Series B and beyond) investments while still maintaining some investment activity in the earlier stage investments, Fund II is now screening investment opportunities where the experience of the OneVentures management team can be leveraged to accelerate value creation and company success.

We are currently looking for truly transformative companies to join our portfolio of innovative companies, if you think your company has what it takes, read our Application for Funding page and submit your application now.

Investment Portfolio

OneVentures Innovation Fund (Fund I)

Other Investments

Latest News

  • Hatchtech Pty Ltd to Explore Strategic Alternatives for Commercialization of Xeglyze™ Lotion in the U.S.

    by OneVentures Administrator | Mar 26, 2015
    Date:18 March, 2015
    Source: Press release
    Company: Hatchtech

    New Drug Application for Xeglyze™ Lotion on Track for 3Q 2015

    MELBOURNE, Australia, March 18, 2015 – Hatchtech Pty Ltd, a specialty pharmaceutical company, today announced that it is exploring strategic alternatives for the possible commercialization in the U.S of its innovative head lice product candidate, Xeglyze™ Lotion. The product is currently on track for a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) in the third quarter of 2015. Hatchtech has retained NY-based investment bank Molecular Securities to act as an advisor in the strategic review.

    “Xeglyze Lotion is emerging as a differentiated development candidate to treat head lice infestations, and we are excited to have progressed the product through to the NDA submission stage,” said Hugh Alsop, chief executive officer of Hatchtech. “As a small, private, single-asset Australian company, we believe that Xeglyze’s true market potential, if approved, may best be promptly realized by a company with an established U.S. marketing presence and a focus on the pediatric market. We have already received interest from several pharmaceutical companies looking to expand their pediatric drug franchises. With the assistance of Molecular Securities, we aim to secure a commercial partner for a U.S. market launch in the event of FDA approval.”

    In September 2014, Hatchtech announced positive results from its two pivotal Phase 3 clinical studies evaluating Xeglyze Lotion as a potential treatment for head lice infestation.  Both studies achieved the pre-defined primary and secondary endpoints and were conducted according to a Special Protocol Assessment (SPA) agreement with the FDA.  The studies were designed to assess the efficacy, safety and tolerability of a single ten minute application of Xeglyze Lotion compared to a vehicle lotion, when applied to the scalp and hair. The results were assessed in follow up visits on days 1, 7 and 14 following application. In both Phase 3 studies, the proportion of patients who were lice free at all follow-up visits through Day 14 were significantly greater compared to the vehicle control. No Xeglyze-related serious adverse events were recorded and no subjects discontinued the study due to an adverse event.

    Abametapir, the active ingredient of Xeglyze Lotion, inhibits metalloproteinases; enzymes that are essential to physiological processes critical for egg development and the survival of nymph and adult lice.  In vitro and ex vivo research has demonstrated that Abametapir not only kills the lice, but also prevents hatching of their eggs.

    According to the Centers for Disease Control & Prevention, in the U.S. there are between six and twelve million cases of head lice infestations among children 3 to 11 years of age annually. The economic cost of head lice infestation in the U.S. has been estimated at $1 billion annually, and includes the adverse impact of classroom absences, school disruption, and parental workday absences. In many cases, existing treatments require more than two topical administrations 7 to 10 days apart. In addition, increased resistance of lice to some of the currently marketed insecticide treatments, such as permethrin, has been reported to reduce their effectiveness.  Market research conducted by Hatchtech with parents and physicians has revealed that, in addition to overall efficacy, a single application without the need for nit combing is a very important product attribute.  Further, the American Academy of Pediatrics Clinical Report on Head Lice states that “Because current products are not completely ovicidal, applying the product at least twice, at proper intervals, is recommended … and manual removal of nits after treatment with any product is recommended by some.”

    Download the press release here

Full story

Contact Us

For Entrepreneurs

Think you have what it takes to join the OneVentures portfolio of companies? Then send one or two pages covering the following to

  • Summarize what your company does / what the technology is in 2 sentences
  • 3 point bios of each executive
  • The problem being addressed
  • The market, the value proposition and your competitive advantage
  • Your progress to date
  • Revenue for the last financial year
  • Projected revenue for current financial year
  • Capital required
  • What the capital will be used for
  • Your contact details

OneVentures focuses on understanding the product attributes, the market, the team, the competition and the stage of maturity of the product.

On receipt of your proposal, it will be reviewed by the OneVentures Partners. Although we receive a great many proposals each week, we endeavour to respond by email to submissions and let you know the Partners' level of interest within two weeks.

For Investors And General Enquiries:

General enquiries:
Investor enquiries:
Telephone: +61 2 8205 7379


OneVentures Pty Ltd
Suite 304, Level 3
1 Alfred Street
Sydney NSW 2000


c/- Interfinancial
Level 3, 145 Eagle Street
Brisbane QLD 4000

For media enquiries

For an interview with a OneVentures' spokesperson, please contact Honner Media at +61 2 8248 3744.